Contribute Try STAT+ Today

Sanofi said Monday that it is acquiring Principia Biopharma for $3.68 billion, giving the French drug giant full control over the multiple sclerosis treatment the companies share.

The deal values Principia at $100 per share, a 10% premium over the company’s closing price Friday, but represents a 35% premium to the price of Principia stock on July 15.  Bloomberg News reported on July 16 that Sanofi was considering making acquisitions, with Principia as a likely target. The deal has been approved by the boards of both companies, Sanofi said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy